ClinicalTrials.gov
ClinicalTrials.gov Menu

Acute Kidney Injury in Patients Undergoing Contrast Exposure: VQ vs. CT (VQ/CT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03116139
Recruitment Status : Recruiting
First Posted : April 14, 2017
Last Update Posted : August 9, 2017
Sponsor:
Collaborator:
National Institutes of Health (NIH)
Information provided by (Responsible Party):
Alice Mitchell, Indiana University

Brief Summary:
Both, CT scans and VQ scans, are used by doctors to look for pulmonary embolism. The most common reason to order a VQ scan is to avoid the IV dye. The IV dye used for CT scans can cause kidney problems in some patients, called contrast-induced nephropathy or "CIN." This is a kidney problem that usually does not make patients feel any differently or change how they urinate. Most of the time, it can only be found by testing blood several days later. This kind of kidney problem can be very mild and some patients will never have any symptoms, rarely these problems can be severe. Some patients can also have similar kidney problems for many other reasons (reactions to medications, blood pressure problems, etc.) and can even happen in patients that do not get IV dye. That is why doctors are not sure exactly who will have these problems or if using a test that does not use IV dye can prevent this kidney problem. The VQ scan uses a different medication through the IV that is not IV dye and has not been linked to kidney problems. The purpose of this study is to learn if using the test that does not use IV dye (the "VQ scan") instead of a CT scan in some patients can help to prevent kidney problems.

Condition or disease Intervention/treatment Phase
Acute Kidney Injury Pulmonary Embolism Contrast-induced Nephropathy Diagnostic Test: V/Q imaging Diagnostic Test: Computed tomography scan Not Applicable

Detailed Description:

Before the study begins, research personnel will do the following to be sure that patients can be in the study:

  • research personnel will talk to the treating physician.
  • research personnel will review the patient medical records, blood and urine tests already done for as usual medical care, and chest X-ray.
  • research personnel will ask the patients some questions about their health.
  • If it has not already been done for usual medical care, patients will be asked to give a urine sample to test for medical conditions that may result in a higher risk of having kidney problems such as having glucose (sugar) in the urine.

If the patient is eligible to continue in the study, the following will also happen at the initial day of enrollment:

  • research personnel will draw about 4 tablespoons of blood from the vein or, if from the IV that was (or will be) placed for usual medical care.
  • If one of the 100 patients who are at low risk of kidney problems, they will have a CT scan of the chest that was ordered by the doctor.
  • Otherwise, the potential subject will be randomly assigned to have either a CT scan of the chest, which will include dye given in an IV, or a VQ scan, that does not use IV dye. One half will have the CT scan and one half will have the VQ scan.
  • Potential subjects will also have an ultrasound (a painless sound wave test of the legs to look for a clot in the legs that can cause a clot in the lungs), if the doctor thinks that one is needed, or if the VQ scan is "indeterminate." Indeterminate means that the radiologist, the doctor reading the VQ scan, cannot tell if there is a pulmonary embolism (a clot in your lung). Research personnel expect that less than 5% (5 out of 100) patients will have a VQ scan that is indeterminate. Some patients who have a VQ scan that is indeterminate, may also need to have a CT scan of their chest to be sure that they do or do not have a clot in their lungs.
  • research personnel will also save blood and urine samples. Later, these samples will be used to test for electrolytes (salts) and proteins (that may help better predict who will get kidney problems. Subjects will not have to pay for these tests because they will not be used for usual medical care. To protect privacy, research personnel will use a code instead of name to label samples. For this reason, research personnel will not be able to tell the results of these tests.
  • If you are not found to be eligible for this study, the reason will be discussed with you and your treating provider. If you are eligible to continue in the study, the following will happen later:
  • Subjects will be given an appointment to return to the hospital between 2 and 7 days from the initial visit. As a reminder, research personnel will give subjects a reminder card; research personnel will call and/or text the subjects, and/or email with reminders. If subjects are still in the hospital during this time, research personnel will visit the subjects in the hospital.
  • At this appointment research personnel will ask some questions about the health, will take about 4 tablespoons of blood and a urine sample. Blood and urine will be used to test for kidney problems. If these tests do show a kidney problems after having IV dye, research personnel will send a letter to notify subjects and the treating physician.
  • In 30 days, research personnel will make 3 attempts to call and ask some questions about the subject's health. If research personnel cannot follow up by telephone, they will also try to contact by text, and/or by mail.
  • research personnel will also review medical records in 7 days, 30 days, and in 1 year.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 700 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: 1 R01 HL132358: The Contribution of Contrast Media Exposure to Acute Kidney Injury in Patients Evaluated for Pulmonary Embolism in the Emergency Care Setting: a Prospective, Randomized Trial
Actual Study Start Date : July 1, 2017
Estimated Primary Completion Date : December 31, 2020
Estimated Study Completion Date : December 31, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
No Intervention: Low risk for kidney injury with use of CT
No randomization due to low risk for kidney injury. 100 patients undergoing CTPA with an estimated risk of CIN <10% (CINRisk Score <2)
Active Comparator: Randomized to V/Q
150 patients with > 25% estimated risk of CIN (CINRisk Score ≥ 2), randomized to VQ imaging (unexposed control)
Diagnostic Test: V/Q imaging
Standard of care
Other Name: Ventilation perfusion scan

Active Comparator: Randomized to CT
150 patients with > 25% estimated risk of CIN (CINRisk Score ≥ 2), randomized to CT (exposure to iodinated contrast media)
Diagnostic Test: Computed tomography scan
Standard of care
Other Names:
  • CT
  • CTPA




Primary Outcome Measures :
  1. Acute kidney injury in subjects exposed and unexposed to iodinated contrast media [ Time Frame: >/= 48 hours to </= 168 hours of enrollment ]
    Creatinine increase >/= 25% of baseline



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age≥18 years
  2. CTPA ordered by the treating provider to evaluate PE.
  3. Pre-test probability of PE ≥2.5% and ≤20% (defined using the PE Pretest Consult Score)
  4. For Randomization to CTPA or VQ imaging: Pre-imaging CIN risk ≥25% (CINRisk Score ≥2 points) • A lower-risk subset of 100 patients (CINRisk Score <2) will be enrolled and followed. These patients will complete the CTPA as ordered by their provider (not randomized). Data from this lower-risk subset, along with high-risk patients randomized to CTPA will be used will be used to validate the CINRisk Score, alone and in combination with NGAL and eGFRCYS (Study Aims 1 and 3).

Exclusion Criteria:

  1. History of pulmonary surgery or pulmonary infiltrate, mass or effusion on chest radiograph.
  2. Inability to provide written informed consent.
  3. Inability to obtain venous blood for baseline creatinine measurement
  4. Clinical instability preventing randomization to CTPA or VQ imaging.
  5. Pregnancy or ≤48 hours post-partum
  6. Subject unavailability for reasonable follow-up including biological sample collection, serum creatinine measurement, and interview, such as an insecure residence, planned travel or absence, personal or professional obligations, incarceration, and/or other reason preventing follow-up, identified at enrollment.
  7. Active renal replacement therapy (hemodialysis or peritoneal dialysis) within 30-days of enrollment or previous physician-directed plans to initiate dialysis within 30-days of the index visit.
  8. Prior renal transplant or planned within 30-days of enrollment.
  9. Intravascular contrast administration within 14 days prior to enrollment or planned within 7 days of enrollment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03116139


Contacts
Contact: Alice Mitchell, MD (317) 880-3900 alimitch@iu.edu
Contact: Cassandra Hall 317-697-2850 clsh@iu.edu

Locations
United States, Indiana
Indiana University Health Methodist Hospital Recruiting
Indianapolis, Indiana, United States, 46202
Contact: Doris Muriathiri, MS    317-962-5024    dmuriath@iu.edu   
Contact: Lexi Geiger, BS    317-880-8012    legeiger@iu.edu   
Sponsors and Collaborators
Indiana University
National Institutes of Health (NIH)

Responsible Party: Alice Mitchell, Assistant Professor of Emergency Medicine, Indiana University
ClinicalTrials.gov Identifier: NCT03116139     History of Changes
Other Study ID Numbers: VQ/CT
1R01HL132358-01A1 ( U.S. NIH Grant/Contract )
First Posted: April 14, 2017    Key Record Dates
Last Update Posted: August 9, 2017
Last Verified: August 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Alice Mitchell, Indiana University:
Computed tomography scan
Ventilation-perfusion lung scan
Acute kidney injury
Pulmonary embolism
Contrast-induced nephropathy

Additional relevant MeSH terms:
Wounds and Injuries
Kidney Diseases
Acute Kidney Injury
Embolism
Pulmonary Embolism
Urologic Diseases
Renal Insufficiency
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases